Heidi Ko
YOU?
Author Swipe
View article: Empowering patients for biomarker-informed care: digital education to bridge HER2-low knowledge gaps in metastatic breast cancer
Empowering patients for biomarker-informed care: digital education to bridge HER2-low knowledge gaps in metastatic breast cancer Open
Background The emergence of trastuzumab deruxtecan has led to significant improvement in clinical outcomes for patients with HER2-low metastatic breast cancer, which accounts for approximately half (45%–55%) of breast cancer diagnoses. How…
View article: CD40 transcriptomic expression patterns across malignancies: implications for clinical trials of CD40 agonists
CD40 transcriptomic expression patterns across malignancies: implications for clinical trials of CD40 agonists Open
Background CD40 is a T-cell co-stimulatory receptor targeted by next-generation immunotherapies. We conducted a pan-cancer transcriptome analysis of CD40, its ligand, and related immune markers to evaluate co-expression patterns and clinic…
View article: RB1 expression and HR proficiency define a poor prognosis subtype of high grade serous ovarian cancer
RB1 expression and HR proficiency define a poor prognosis subtype of high grade serous ovarian cancer Open
High-grade serous ovarian carcinoma (HGSOC) is a molecularly heterogeneous and lethal malignancy, with late-stage diagnosis contributing to high risk of recurrence and poor clinical outcomes. Although homologous recombination (HR) deficien…
View article: RB1 expression and HR proficiency define a poor-outcome molecular subtype of high grade serous ovarian carcinoma
RB1 expression and HR proficiency define a poor-outcome molecular subtype of high grade serous ovarian carcinoma Open
High-grade serous ovarian carcinoma (HGSOC) is a molecularly heterogeneous and lethal malignancy, with late-stage diagnosis contributing to high risk of recurrence and poor clinical outcomes. While homologous recombination (HR) deficiency …
View article: Pilot phase <scp>II</scp> study of the combination of lenvatinib (L) and eribulin (E) in advanced solid tumors
Pilot phase <span>II</span> study of the combination of lenvatinib (L) and eribulin (E) in advanced solid tumors Open
This pilot phase II study evaluated the combination of lenvatinib, a multi‐kinase inhibitor, and eribulin, a microtubule inhibitor, in patients with advanced solid tumors, including breast carcinoma, lung carcinoma, and sarcoma. Tumor angi…
View article: From tissue-specific to tissue-agnostic: HER2 overexpression and the rise of antibody-drug conjugates
From tissue-specific to tissue-agnostic: HER2 overexpression and the rise of antibody-drug conjugates Open
The growing importance of HER2 expression as a biomarker across multiple cancers is largely driven by advances in HER2-directed antibody-drug conjugates. The recent approval of trastuzumab deruxtecan (T-DXd) as a tumor-agnostic therapy has…
View article: Analysis of real world FRα testing in ovarian, fallopian tube, and primary peritoneal cancers
Analysis of real world FRα testing in ovarian, fallopian tube, and primary peritoneal cancers Open
Preliminary findings from this study were previously presented in poster format at the Society of Gynecologic Oncology 2024 Annual Metting. We confirm that the submission complies with the journal requirements.
View article: Case report: Single gene testing and comprehensive genomic profiling in non-small cell lung cancer—a case series of divergent results from a large reference laboratory
Case report: Single gene testing and comprehensive genomic profiling in non-small cell lung cancer—a case series of divergent results from a large reference laboratory Open
Clinical management of non-small cell lung cancer (NSCLC) requires accurate identification of tumor-specific genetic alterations to inform treatment options. Historically, providers have relied on single-gene testing (SGT) for actionable v…
View article: Biomarkers in head and neck squamous cell carcinoma: unraveling the path to precision immunotherapy
Biomarkers in head and neck squamous cell carcinoma: unraveling the path to precision immunotherapy Open
Recent strides in understanding the molecular underpinnings of head and neck cancers have sparked considerable interest in identifying precise biomarkers that can enhance prognostication and enable personalized treatment strategies. Immuno…
View article: A consensus-based classification workflow to determine genetically inferred ancestry from comprehensive genomic profiling of patients with solid tumors
A consensus-based classification workflow to determine genetically inferred ancestry from comprehensive genomic profiling of patients with solid tumors Open
Disparities in cancer diagnosis, treatment, and outcomes based on self-identified race and ethnicity (SIRE) are well documented, yet these variables have historically been excluded from clinical research. Without SIRE, genetic ancestry can…
View article: 4‐1BB transcriptomic expression patterns across malignancies: Implications for clinical trials of 4‐1BB agonists
4‐1BB transcriptomic expression patterns across malignancies: Implications for clinical trials of 4‐1BB agonists Open
4-1BB, a member of the tumor necrosis factor receptor superfamily, is an important co-stimulatory molecule regulating the activity of immune cells across a range of physiological and pathological processes, which culminates in a potent imm…
View article: Comprehensive Assessment of Immune Phenotype and Its Effects on Survival Outcomes in HER2-Low versus HER2-Zero Breast Cancer
Comprehensive Assessment of Immune Phenotype and Its Effects on Survival Outcomes in HER2-Low versus HER2-Zero Breast Cancer Open
Patients with HER2-low breast cancer have longer survivals yet display no differences in immune-related gene expression when compared to those with HER2-zero cancers. The differences in survival can be attributed to the higher rate of ER-p…
View article: Real-world comprehensive genomic and immune profiling reveals distinct age- and sex-based genomic and immune landscapes in tumors of patients with non-small cell lung cancer
Real-world comprehensive genomic and immune profiling reveals distinct age- and sex-based genomic and immune landscapes in tumors of patients with non-small cell lung cancer Open
Introduction Younger patients with non-small cell lung cancer (NSCLC) (<50 years) represent a significant patient population with distinct clinicopathological features and enriched targetable genomic alterations compared to older patien…
View article: Immunologic Factors Associated with Differential Response to Neoadjuvant Chemoimmunotherapy in Triple-Negative Breast Cancer
Immunologic Factors Associated with Differential Response to Neoadjuvant Chemoimmunotherapy in Triple-Negative Breast Cancer Open
Background: KEYNOTE-522 resulted in FDA approval of the immune checkpoint inhibitor pembrolizumab in combination with neoadjuvant chemotherapy for patients with early-stage, high-risk, triple-negative breast cancer (TNBC). Unfortunately, p…
View article: The Impact of Prior Single-Gene Testing on Comprehensive Genomic Profiling Results for Patients with Non-Small Cell Lung Cancer
The Impact of Prior Single-Gene Testing on Comprehensive Genomic Profiling Results for Patients with Non-Small Cell Lung Cancer Open
For patients with NSCLC, initial use of SGT increases subsequent CGP test cancellations, turnaround time, and the likelihood of incomplete molecular profiling for guideline-recommended biomarkers due to tissue insufficiency.
View article: 176 Immune microenvironment of primary versus metastatic melanoma of the brain
176 Immune microenvironment of primary versus metastatic melanoma of the brain Open
Background Immune checkpoint inhibitors (ICIs) have revolutionized the treatment of melanoma resulting in improved clinical outcomes, however approximately 50% of patients ultimately develop resistance and progress on ICPI. Significant cli…
View article: 183 Comprehensive genomic and immune profiling (CGIP) reveals a distinct genomic and immune gene expression profile for younger patients with non-small cell lung cancer (NSCLC)
183 Comprehensive genomic and immune profiling (CGIP) reveals a distinct genomic and immune gene expression profile for younger patients with non-small cell lung cancer (NSCLC) Open
Background NSCLC tumors in younger patients may be enriched for targetable genomic alterations, yet these patients have lower rates of insurance coverage for tissue-based genomic profiling compared to older patients who are Medicare-eligib…
View article: 1499 Molecular and immune profiling of lobular-enriched versus non-lobular invasive breast cancers
1499 Molecular and immune profiling of lobular-enriched versus non-lobular invasive breast cancers Open
Background Invasive lobular carcinoma (ILC) is a morphologically distinct endocrine-sensitive sub-type of invasive breast cancer. Invasive ductal carcinoma has been extensively characterized, however, the genomic and immune characteristics…
View article: 175 Metastatic triple negative breast cancer has distinct tumor immune landscape
175 Metastatic triple negative breast cancer has distinct tumor immune landscape Open
Background Triple negative breast cancer (TNBC) is considered the most immunogenic breast cancer subtype due to higher levels of tumor infiltrating immune cells (TILS), elevated tumor mutational burden and PD-L1 expression, providing a rat…
View article: 513 Comprehensive genomic and immune profiling of ALK fusion-positive and negative lung adenocarcinomas
513 Comprehensive genomic and immune profiling of ALK fusion-positive and negative lung adenocarcinomas Open
Background ALK rearrangements are known drivers of a subset of lung adenocarcinomas (LAs), and ALK fusion-positive tumors are associated with reduced efficacy of PD-1/PD-L1 immune checkpoint inhibition. Precise knowledge of the molecular d…
View article: Older Age and Neutrophil-to-Lymphocyte Ratio (NLR) Are Predictors of Illness Severity and COVID-Related Mortality in a Multiethnic Urban Cohort of Hematologic Neoplasms Patients: An Updated Analysis
Older Age and Neutrophil-to-Lymphocyte Ratio (NLR) Are Predictors of Illness Severity and COVID-Related Mortality in a Multiethnic Urban Cohort of Hematologic Neoplasms Patients: An Updated Analysis Open
Introduction: We have previously shown that older age and increased NLR were associated with worse outcomes among patients with hematologic neoplasms diagnosed with COVID-19 from March to June 2020. We sought to perform an updated and expa…
View article: Older Age and Increased Neutrophil-to-Lymphocyte Ratio (NLR) Are Predictors of Mortality in a Multiethnic Urban Cohort of Hematologic Neoplasms and COVID-19 Patients
Older Age and Increased Neutrophil-to-Lymphocyte Ratio (NLR) Are Predictors of Mortality in a Multiethnic Urban Cohort of Hematologic Neoplasms and COVID-19 Patients Open
Introduction: We sought to compare outcomes among patients with hematologic neoplasms diagnosed with COVID-19 infection in a multiethnic urban academic medical center. Methods: A retrospective analysis of patients with hematologic neoplasm…
View article: Clinical Utility of 18F-FDG PET/CT in Staging Localized Breast Cancer Before Initiating Preoperative Systemic Therapy
Clinical Utility of 18F-FDG PET/CT in Staging Localized Breast Cancer Before Initiating Preoperative Systemic Therapy Open
Background: 18 F-fluorodeoxyglucose PET/CT is recommended as an optional study in the current NCCN Clinical Practice Guidelines in Oncology for Breast Cancer after CT of the chest, abdomen, and pelvis with contrast and bone scan (CTBS) in …